Methods: This is a sub study of the all-comers EXAMINATION Trial that randomized 1498 patients with STEMI undergoing percutaneous coronary intervention (PCI) to EES or BMS. For the purpose of this substudy, the patient-oriented combined endpoint of all-cause death, any recurrent myocardial infarction and any revascularization, target lesion revascularization and stent thrombosis rates were analyzed according to the gender at 2-year follow-up. Results: Out of 1498 patients included in the trial, 254 (17.0%) women were included and randomized to BMS (n¼137, 53.9%) or EES (n¼117, 46.1%). Women were older (67.9 vs. 59.8; p<0.01), had higher prevalence of hypertension (62.2% vs. 45.6%; p<0.01) and a lower prevalence of smoking (36.6% vs. 79.5%; p<0.01) as compared with men. Also women had a lower use of thrombectomy (59.1% vs. 66.4%; p¼0.02) and IIb/IIIa inhibitor than men (44.9% vs. 53.9%, p<0.01). In contrast with men, stent diameter was smaller in women (3.07 mm vs. 3.23 mm, p<0.01). Compliance of dual antiplatelet therapy at one year was lower in women than in men. After adjustment per confounders, the primary endpoint was similar between men and women (HR 0.95; 95%CI 0.66-1.37) and within women, between those treated with BMS versus EES (HR 1.54: 95%CI 0.77-3.11). Women showed a lower rate of repeat revascularization than men (HR 0.55; Background: Intraprocedural thrombotic events (IPTE) during percutaneous coronary intervention (PCI) are associated with adverse outcomes in patients with both non-STsegment elevation and ST-segment elevation acute coronary syndromes (NSTEACS/ STEMI). We have previously validated the occurrence of IPTE to be a powerful independent predictor of early and late major adverse cardiac events (MACE) after PCI. The extent to which individual components of IPTE are associated with adverse events is unknown. Methods: A total of 6,591 patients who received PCI for NSTEACS/STEMI in the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) and Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trials underwent detailed frame-by-frame core laboratory angiographic analysis to assess for IPTE. IPTE was defined as the occurrence of new/worsened thrombus, abrupt closure, no reflow/slow flow, distal embolization, or intraprocedural stent thrombosis (IPST). The independent associations of IPTE components with death, major bleeding, and MACE at 30-days were assessed using multivariable models. Results: The overall incidence of IPTE was 7.8%. Among patients with IPTE, no reflow/slow reflow was present in 58.0%, new/worsened thrombus in 35.3%, distal embolization in 34.9%, abrupt closure in 19.8%, and IPST in 9.5% of patients. Each IPTE component was associated with 30-day death, major bleeding, and MACE in multivariable models (Table) , with the strongest association observed for IPST.
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Conclusions:
The occurrence of IPTE is not infrequent among high-risk ACS patients undergoing PCI. The single component with the strongest association with adverse events was IPST, which fortunately represented <10% of IPTE events overall. Future therapeutic strategies aimed at minimizing the occurrence and consequences of IPTE are warranted. Humanitas Institute, Milan, ID Background: Women are at high risk for mortality after ST-elevation acute myocardial infarction (STEMI). Whether sex-disparities still exist in the treatment and mortality of patients after STEMI remains controversial. The aim of this study was to assess recent trends in hospital mortality and in treatment modalities for patients with STEMI according to sex. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com B80 JACC Vol 62/18/Suppl B j October 27-November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS Methods: Data on hospitalizations for STEMI from 2000 through 2010 were extracted from hospital discharge record databases from all hospitals in Lombardia (a Northern Italy region with high density population). Main outcome measures were inhospital mortality and treatment modality by sex. Treatment modalities included medical therapy alone or an invasive approach, the latter consisting of coronary angiography alone, percutaneous coronary intervention (PCI), or coronary artery bypass graft surgery. Multivariable logistic regression was performed to assess the impact of female sex and of treatment modality on mortality after adjusting for age, and comorbidities.
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Results: A total of 92807 patients with STEMI, 66.4% men and 33.6% women were enrolled. Women were older than men (mean 75.1 yrs vs 64.1 yrs, p<0.0001) and had a higher prevalence of chronic renal failure (p<0.001). In-hospital mortality presented a small decrease from 7.5% in 2000 to 6.3% in 2010 among men, while it remained higher and substantially constant over time among women (16.4% in 2000, 16.2% in 2010) . The use of an invasive approach increased over time in both sexes (from 55% in 2000 to 91% in 2010 in men and from 36% in 2000 to 70% in 2010 in women). The use of PCI increased from 32% in 2000 to 82% in 2010 in men; and from 21% in 2000 to 57% in 2010 in women. At multivariable regression, an invasive approach (odds ratio (OR) 0.23, 95% confidence interval (CI), 0.21-0.25, p<0.001) was associated with a significant reduction in mortality, while female sex was not a predictor of mortality (OR 0.96, P¼0.18) .
Conclusions: In-hospital mortality remains higher in women than in men, although female sex is not a significant predictor of mortality. Despite temporal increases in the use of an invasive approach, women are more often treated conservatively.
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Characterization The risk for recurrent ischemic events following ST-segment elevation myocardial infarction (STEMI) gradually declines. However, current guidelines suggest consistent therapy from presentation out to 12 months. We sought to characterize the actuarial daily ischemic risk (ADIR) in the 12 months year after STEMI. Methods: Ischemic event rates for all 3602 patients enrolled in the prospective HORIZONS-AMI trial were categorized according to the timing of their occurrence in three groups: Group 1: during index hospitalization, Group 2: from hospital discharge to 30 days, and Group 3: from 30 days post hospital discharge to 1 year. Ischemic events included: All-cause death, cardiovascular (CV) death, non-CV death, reinfarction (MI), definite ST and the composite of CV death, MI or definite ST. The ADIR for each event was calculated based on the actual patient days of follow-up for each group. Results: Highly significant reductions in ADIR were observed as patients transitioned from Group 1 to Groups 2 and 3 respectively (Table) . The degree of ADIR reduction approached or exceeded a full order of magnitude for all events except for non-CV death. Accordingly, the relative risk for the composite of CV death, MI or definite p<0 .0001) for Group 1 vs. Group 2, 6.31 (4.62 -8.62, p<0.0001) for Group 2 vs. p<0 .0001) for Group 1 vs. Group 3. Conclusions: Conclusions: The risk for CV death and recurrent ischemic events following an index STEMI treated with primary PCI dramatically declines following hospital discharge out to the first 30 days and declines even further between day 30 and one year. These data suggest that a tailored approach to anti-ischemic protection, with more potent agents administered in the acute and sub-acute phases and less potent agents (with lower bleeding potential) administered after 30 days, warrants investigation. 
